ViiV Healthcare Challenges HIV Treatment Standards with Dovato vs. Biktarvy Data — ViiV Healthcare Limited

Event summary

ViiV Healthcare will present phase IIIb data comparing Dovato (DTG/3TC) with Biktarvy (BIC/FTC/TAF) in treatment-naïve adults at AIDS 2026.
Late-breaking LATA study results will evaluate long-acting injectable HIV treatment in adolescents across sub-Saharan Africa.
New data from OPERA cohort will compare virologic effectiveness of injectable CAB+RPV LA versus daily oral BIC/FTC/TAF.
EXTEND 4M trial will assess a new formulation of CAB LA dosed three times a year for HIV prevention.

The big picture

ViiV Healthcare's presentation at AIDS 2026 underscores a strategic push to validate its integrase strand transfer inhibitor (INSTI)-focused portfolio, particularly long-acting injectables and simplified regimens. The data could reshape treatment paradigms for HIV, especially in resource-limited settings. With GSK as majority owner and Shionogi as a shareholder, ViiV Healthcare is leveraging clinical evidence to maintain its leadership in HIV therapy innovation.

What we're watching

Treatment Efficacy: Whether Dovato's 2-drug regimen can demonstrate non-inferiority to Biktarvy's 3-drug regimen in treatment-naïve adults.
Long-Acting Injectables: The pace at which long-acting injectable HIV treatments gain acceptance among adolescents and high-risk populations.
Market Differentiation: How ViiV Healthcare positions its INSTI-focused portfolio against competitors in the evolving HIV treatment landscape.